ReviewThe Lancet. Global health2021
A global call for talaromycosis to be recognised as a neglected tropical disease.
Review in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- The added value of metagenomic next-generation sequencing in central nervous system infections: a systematic review of case reports.Infection · 2025Pooled it
- GastrointestinalFrontiers in immunology · 2022Pooled it
- Development and Clinical Evaluation of a Novel Talaromyces marneffei Mp1p Lateral Flow Assay for Rapid Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Metagenomic next-generation sequencing of cerebrospinal fluid reveals pathogen spectrum and mortality predictors among patients with advanced HIV-1 disease at a tertiary hospital in China.Virology journal · 2026Article
- Epidemiology and factors associated with Talaromyces marneffei detection in the mainland of China, 2022-2024: a cross-sectional study of hospitalized patients.BMC public health · 2026Article
- In Vitro Evaluation of Olorofim and Amphotericin B Combination Therapy AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Talaromyces marneffei infection of central nervous system in an immunocompetent child in a nonendemic area: a case report and literature review.BMC pediatrics · 2026Review
- AIDS patients with Talaromycosis Marneffei exhibit inflammatory activation and depletion in their peripheral blood monocytes.PLoS neglected tropical diseases · 2026Article
- Sequential Organ Failure Assessment (SOFA) score and quick SOFA(qSOFA) predict 30-day mortality in patients with HIV-associated Talaromycosis: A multicenter retrospective cohort study.PLoS neglected tropical diseases · 2026Article
- Antigen detection of Talaromyces infection in the US: Case report.Medical mycology case reports · 2026Article
- Recent Advances in the Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Treg Cells Impair Talaromyces Marneffei Clearance by Promoting M2 Macrophage Polarization Via the IL-10/IL-10R/STAT3 Axis.Inflammation · 2026Article
- Clinical Features and Diagnostic Challenges ofInfection and drug resistance · 2026Article
- STAT1-L351F is associated with enhanced interferon signaling and susceptibility toFrontiers in immunology · 2026Article
- The Role of Talaromyces Marneffei Binding To CD86 in the CD86-CTLA4 Regulatory Pathway.Current microbiology · 2025Article
- HIV infection complicated with talaromyces marneffei, tuberculosis, hemophagocytic lymphohistiocytosis and non-Hodgkin lymphoma: a complex case report.BMC infectious diseases · 2025Article
- In vitro evidence to support amphotericin B and flucytosine combination therapy for talaromycosis.PLoS neglected tropical diseases · 2025Article
- Environmental transmission from bamboo rats: Mapping current and future talaromycosis risk in China under climate change.One health (Amsterdam, Netherlands) · 2025Article
- Two-threshold defined immune non-responders are associated with long-term morbidity in people with HIV: a prospective cohort study.Emerging microbes & infections · 2025Article
- Clinical spectrum of Talaromyces marneffei infections in HIV-negative patients: an 18-case series including a rare presentation with gastrointestinal onset, adrenal mass, and hemophagocytic lymphohistiocytosis.BMC infectious diseases · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 15 institutions in 11 countries.
Funding
Abstract
Talaromycosis (penicilliosis) is an invasive mycosis that is endemic in tropical and subtropical Asia. Talaromycosis primarily affects individuals with advanced HIV disease and other immunosuppressive conditions, and the disease disproportionally affects people in low-income and middle-income countries, particularly agricultural workers in rural areas during their most economically productive years. Approximately 17 300 talaromycosis cases and 4900 associated deaths occur annually. Talaromycosis is highly associated with the tropical monsoon season, when flooding and cyclones can exacerbate the poverty-inducing potential of the disease. Talaromycosis can present as localised or disseminated disease, the latter causing cutaneous lesions that are disfiguring and stigmatising. Despite up to a third of diagnosed cases resulting in death, talaromycosis has received little attention and investment from regional and global funders, policy makers, researchers, and industry. Diagnostic and treatment modalities remain extremely insufficient, however control of talaromycosis is feasible with known public health strategies. This Viewpoint is a global call for talaromycosis to be recognised as a neglected tropical disease to alleviate its impact on susceptible populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.